A comprehensive view of Prescription Drugs. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Consumer Wellness Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Eli Lilly and plaintiffs abandon proposed US$13.5M settlement regarding alleged overpricing of insulin; the move follows a court ruling against certifying specific state-classes in the case
Published: April 17, 2024 by FiercePharma
GlobalData: Eli Lilly set to reshape pharmaceutical landscape with obesity and Alzheimer's treatments, Mounjaro and donanemab; both drugs poised to beat market expectations, with Mounjaro's sales poised to reach US$34B in 2029, more than double Wegovy's
Published: April 17, 2024 by GlobalData Plc
GlobalData predicts GLP-1 drugs will redefine big pharma sales; Eli Lilly's diabetes drug, Mounjaro, is forecasted to generate US$34.0B by 2029, surpassing the entire 2023 portfolio of Lilly, with the Alzheimer's drug donanemab adding another US$5.0B
Published: April 17, 2024 by FiercePharma
Three US Senators to question Novo Nordisk over the discontinuation of Levemir, a long-acting insulin, just before a significant price cut was due to take effect; over seven million patients in the US rely on insulin
Published: April 17, 2024 by ForeignAffairs.co.nz
Abbott reports Q1 profit of US$1.23B, revenue of US$9.96B, surpassing Wall Street expectations
Published: April 17, 2024 by Associated Press

Ask us about our Consumer Wellness market view

Trending Chart

Interactive chart with headline count